Galectin Therapeutics (GALT)

• Market cap: $196M
• 1 day: -8.05%
• 5 days: -15.14%
• 1 month: -35.99%
• 3 months: 30.84%
• 6 months: -1%
• Year to date: -26.67%
• 1 year: -18.41%
• 5 years: -6.31%
• 10 years: 54.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 9